Cisplatin macrophage
WebApr 14, 2024 · Other lines of research have revealed a relationship between HAT-1 and hepatocellular carcinoma (HCC) treatment with cisplatin, which is commonly associated with drug resistance in patients with this cancer . Notably, ... As a monocyte- and macrophage-specific scavenger receptor (CD163) that is shed into plasma, soluble … WebNov 30, 2024 · For the first time, in vitro studies on cisplatin exposure addressed human monocytes and monocyte-derived macrophages (undifferentiated THP-1 monocytic …
Cisplatin macrophage
Did you know?
WebNov 1, 2014 · Cisplatin, a member of platinum agents, is one of the most widely used anticancer chemical drugs and a part of the treatment to many types of solid tumors, including head and neck, breast, testicular, ovarian, cervical, lung, and colorectal cancers (Rabik & Dolan, 2007 ). WebFeb 7, 2024 · In the present study, we investigated the effects of magnolol on muscle wasting and macrophage subtypes in a cisplatin-induced sarcopenia mouse model. We showed that magnolol significantly attenuated the body weight and the muscle loss induced by cisplatin injection.
WebApr 1, 2016 · Cisplatin is currently one of the most effective chemotherapeutic drugs used for treating ovarian cancer; however, resistance to cisplatin is common. In this study, we explored an experimental strategy for overcoming cisplatin resistance of human ovarian cancer from the new perspective of cancer cell metabolism.
WebMar 20, 2024 · This study was designed to investigate whether the oral administration of M.C could decrease cisplatin-induced sarcopenia by modulating M2 macrophage polarization in mice. C57BL/6 mice were injected intraperitoneally with cisplatin (2.5 mg/kg) to mimic chemotherapy-induced sarcopenia. WebMar 10, 2024 · Original research: CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype - PMC Back to Top Skip to main content An official website of the United States government Here's how you know The .gov means it’s official.
WebJun 11, 2024 · VNS treatment significantly suppressed cisplatin-induced kidney injury. This effect was abolished by splenectomy, while adoptive transfer of GTS-21-treated …
WebCisplatin (DDP) is a common therapeutic option for non-small cell lung carcinoma (NSCLC). However, some patients fail to respond to the DDP chemotherapy. Therefore, identifying novel biomarkers to improve the diagnosis and treatment of NSCLC is important. Ubiquitin-specific protease (USP14) is involved in various pathological conditions ... fmcsa records retentionWebApr 11, 2024 · 2024年查处的不端行为案件处理结果通报（第一批次）. 近期，经国家自然科学基金委员会监督委员会调查审议、国家自然科学基金委员会委务会议审定，国家自然科学基金委员会对相关科研不端案件涉事主体进行了处理。. 现将给予通报批评的有关案情及处理 ... greensboro sheriff deptWebJan 24, 2024 · The results suggested that SQFZ could inhibit MDA-MB-231/DDP cell growth related to M2 macrophages. When cisplatin was used in combination with SQFZ 40 … fmcsa reflective tapeWebMar 18, 2024 · Salvagno et al. 4 found that neutrophils, but not macrophages, limit tumour response to cisplatin by suppressing CD8 + … fmcsa rear bumper regulationsWebNational Center for Biotechnology Information greensboro sheraton hotelWebAug 24, 2024 · 1. Introduction. Cisplatin (CDDP), a platinum-based anticancer agent, is one of the most commonly used chemotherapy drugs in the treatment of patients with various types of cancer, such as bladder, ovarian, head and neck, lung, testicular, cervical, esophageal, and breast cancer [].CDDP and its analogs, carboplatin and oxaliplatin, … fmcsa refresher trainingWebSep 13, 2024 · Our findings in cisplatin-induced injury underscore the value of dissecting the functions of individual MP subsets in kidney disease, which may enable therapeutic targeting of specific immune components in the absence of general immunosuppression. Sign up for PNAS alerts. Get alerts for new articles, or get an alert when an article is cited. fmcsa refresher course